2025 revenue increased 95% year-over-year to $819 thousand from $420 thousand in 2024. Gross margin improved to 92.3% in 2025 from 90.0% in 2024. Net loss for 2025 was $17.2 million, including $7.8 million in non-cash expenses, compared to a net loss of $16.6 million with $7.5 million non-cash in 2024. Q4 2025 revenue increased 60% to $238 thousand compared to $148 thousand in Q4 2024. Q4 2025 gross margin was 91.6% compared to 92.6% in Q4 2024. Q4 2025 net loss was $5.3 million, including $3.5 million in non-cash expenses, compared to a net loss of $5.6 million with $3.1 million non-cash in Q4 2024. Acquired Flyte, Inc., a regional air mobility company, diversifying into two distinct business segments: Medical Device Platform (VIVO & LockeT) and Aviation Platform (Flyte). Achieved CE Mark for LockeT in April 2025 and initiated first commercial LockeT sales in Europe. Added 32 new customers across VIVO and LockeT platforms. Four abstracts accepted at the annual Heart Rhythm Society Meeting. Completed financing initiatives to strengthen the balance sheet and support growth strategy.